0001213900-24-020882.txt : 20240308 0001213900-24-020882.hdr.sgml : 20240308 20240308083856 ACCESSION NUMBER: 0001213900-24-020882 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240308 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240308 DATE AS OF CHANGE: 20240308 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Allarity Therapeutics, Inc. CENTRAL INDEX KEY: 0001860657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41160 FILM NUMBER: 24732441 BUSINESS ADDRESS: STREET 1: 24 SCHOOL ST., 2ND FLOOR CITY: BOSTON STATE: MA ZIP: 02108 BUSINESS PHONE: 401-426-4664 MAIL ADDRESS: STREET 1: 24 SCHOOL ST., 2ND FLOOR CITY: BOSTON STATE: MA ZIP: 02108 8-K 1 ea0201409-8k_allarity.htm CURRENT REPORT
false 0001860657 0001860657 2024-03-08 2024-03-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 8, 2024

 

ALLARITY THERAPEUTICS, INC.

(Exact name of registrant as specified in our charter)

 

Delaware   001-41160   87-2147982
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

24 School Street, 2nd Floor

Boston, MA

  02108
(Address of principal executive offices)   (Zip Code)

 

(401) 426-4664

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ALLR   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On March 8, 2024, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, certain financial and operational information for its fiscal year ended December 31, 2023 and provided a business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. 

 

Item 7.01 Regulation FD Disclosure.

 

The information included in Item 2.02 above is incorporated herein by reference. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

This information is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, unless we specifically incorporate it by reference in a document filed under the Securities Act of 1933 or the Securities Exchange Act of 1934. By furnishing this information on this Current Report on Form 8-K, we make no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. 

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit
Number
  Exhibit Description
99.1   Press Release dated March 8, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on our behalf by the undersigned hereunto duly authorized.

 

  Allarity Therapeutics, Inc.
   
Date: March 8, 2024 By:  /s/ Thomas Jensen
    Thomas Jensen
    Chief Executive Officer

 

 

2

 

 

EX-99.1 2 ea020140901ex99-1_allarity.htm PRESS RELEASE DATED MARCH 8, 2024

Exhibit 99.1

 

 

Allarity Therapeutics Reports Full Year 2023
Financial Results and Provides a Business Update

 

 

 Leadership Changes Led by Appointment of Co-Founder Thomas Jensen as Interim CEO and Jeremy Graff, Ph.D., former Eli Lilly Executive, as Executive Advisor

 

Reduced Net Loss from Operations by 50% and Reduced Net Loss by 26%

 

- Announced Data in December 2023 from Advanced Ovarian Cancer Phase 2 Stenoparib Study Showing Significant Clinical Benefit

 

Boston (March 8, 2024) — Allarity Therapeutics, Inc. (“Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results for the year ended December 31, 2023, and provided a general business update.

 

The Company’s Interim Chief Executive Officer, Thomas Jensen, stated, “2023 was a year of remarkable achievements for Allarity Therapeutics as we made significant strides in advancing our DRP®-guided drug development. Our clinical research has shown strong indications that we can address a significant unmet medical need in oncology. In particular, our lead asset, stenoparib, has demonstrated exceptional promise in advanced ovarian cancer trials. As we continue through 2024, our focus remains on continuing to generate and report on additional pivotal clinical trial data for stenoparib, which we expect will further strengthen interest in our work from a broad group of stakeholders, including leading oncologists, potential partner companies, and the biotech investor community.”

 

2023 Highlights and Recent Developments

 

Stenoparib (2X-121): An orally available, small molecule dual-targeted inhibitor of poly-ADP ribose polymerase (PARP1/2) and telomerase maintenance enzymes (Tankyrase 1 and 2) in development for advanced ovarian cancer.

 

Early data announced in December 2023 from the Phase 2 monotherapy study of stenoparib for advanced ovarian cancer showed significant clinical benefit in evaluable patients following a protocol change to twice-daily dosing earlier in the year. Using the DRP®-Stenoparib companion diagnostic (CDx), which includes 414 mRNA biomarkers, patients were selected based on a DRP score above 50%. Of 22 screened, 17 were DRP positive, with 11 treated, of which five were evaluable before the data evaluation cut-off. One trial participant showed a complete response in December 2023, and the other four evaluable patients had stable diseases, all were previously treated with PARP inhibitors and chemotherapy.

 

 

Allarity Therapeutics, Inc. | 210 Broadway, #201 | Cambridge, MA | U.S.A. | NASDAQ: ALLR | www.allarity.com

 

Page 1 of 6

 

 

Announced leadership changes and strategic advisory engagement:

 

Appointment of co-founder Thomas H. Jensen as Interim Chief Executive Officer in December 2023. With nearly two decades at Allarity Therapeutics, Jensen brings extensive experience and a deep understanding of the company’s DRP® to his new role. Mr. Jensen has been instrumental in developing molecular biological techniques essential for the DRP platform and played a key role in building investor relations and securing financing.
   
Engaged Jeremy R. Graff, Ph.D., as an Executive Advisor. Dr. Graff, with over 25 years of experience in biotech and pharma, is a specialist in both developing clinical strategy and successful execution of numerous clinical development programs of cancer therapeutics. His notable career includes C-level positions and a significant tenure at Eli Lilly, where he led the translational oncology group.

 

Anticipated Clinical Milestones in 2024

 

The focus of the Company remains on generating and disclosing pivotal clinical data to demonstrate the clinical benefit of our DRP guided therapies. Accordingly, we expect to announce interim data from the DRP®-guided Phase 2 clinical trial of stenoparib in advanced ovarian cancer during the second quarter of 2024. We believe that this milestone is particularly significant as it will provide further insights into stenoparib’s potential to meet the unmet needs in the treatment of advanced ovarian cancer.

 

Full Year 2023 Operating Results

 

R&D Expenses: Research and Development (R&D) expenses were $7.1 million for 2023, compared to $6.9 million for 2022.

 

G&A Expenses: General and Administrative (G&A) expenses were $10.0 million for 2023, compared to $10.0 million for 2022.

 

Net Loss from Operations: Net Loss from Operations was $17.1 million for 2023, compared to $34 million for 2022.

 

Net Loss: Net loss was $11.9 million for 2023, compared to $16.1 million for 2022.

 

About the Drug Response Predictor – DRP® Companion Diagnostic

 

Allarity uses its drug-specific DRP® to select those patients who, by the expression signature of their cancer, are found to have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be significantly increased. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical studies that were examined (both retrospective and prospective). The DRP platform, which can be used in all cancer types and is patented for more than 70 anti-cancer drugs, has been extensively published in the peer-reviewed literature.

 

About Allarity Therapeutics

 

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit www.allarity.com.

 

 

Allarity Therapeutics, Inc. | 24 School Street, 2nd Floor | Boston, MA | U.S.A. | NASDAQ: ALLR  | www.allarity.com

 

Page 2 of 6

 

 

Follow Allarity on Social Media

 

LinkedIn: https://www.linkedin.com/company/allaritytx/

X: https://twitter.com/allaritytx

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s current expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements related to release of the clinical trial data in 2024 and its impact on strengthening interest in our work, the availability of interim/final data readout from the DRP guided Phase 2 clinical trial of stenoparib for advanced ovarian cancer, the possibility of a financing in Q1 2024 and expected availability of capital to fund its anticipated clinical trials, any statements related to ongoing clinical trials for stenoparib as a monotherapy or in combination with another therapeutic candidate for the treatment of advanced ovarian cancer, or ongoing clinical trials (in Europe) for IXEMPRA® for the treatment of metastatic breast cancer, statements relating to the effectiveness of the Company’s DRP® companion diagnostics platform in predicting whether a particular patient is likely to respond to a specific drug and statements related to the Company’s ability to regain compliance with the Nasdaq Listing Rule. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive reviews of the data, and as more patient data become available, the risk that results of a clinical study are subject to interpretation and additional analyses may be needed and/or may contradict such results, the receipt of regulatory approval for stenoparib or any of our other therapeutic candidates and companion diagnostics or, if approved, the successful commercialization of such products, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our therapeutic candidates, and the risk that the current COVID-19 pandemic will impact the Company’s current and future clinical trials and the timing of the Company’s preclinical studies and other operations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Form S-1 registration statement filed on October 30, 2023, as amended and our Form 10-K annual report on file with the Securities and Exchange Commission (the “SEC”), available at the SEC’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

 

 

Allarity Therapeutics, Inc. | 24 School Street, 2nd Floor | Boston, MA | U.S.A. | NASDAQ: ALLR  | www.allarity.com

 

Page 3 of 6

 

 

ALLARITY THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
For the years ended December 31, 2023 and 2022
(U.S. dollars in thousands, except for share and per share data)

 

   2023   2022 
Operating expenses:          
Research and development  $7,103   $6,930 
Impairment of intangible assets       17,571 
General and administrative   10,026    9,962 
Total operating expenses   17,129    34,463 
Loss from operations   (17,129)   (34,463)
Other income (expenses)          
Income from the sale of IP       1,780 
Interest income   22    30 
Interest expenses   (498)   (223)
Loss on investment       (115)
Foreign exchange gains (losses)   133    (913)
Fair value of inducement warrants   (4,189)    
Loss on modification of warrants   (591)    
Change in fair value adjustment of warrant derivative liabilities   10,434    17,125 
Penalty on Series A Preferred stock liability       (800)
Net other income, net   5,311    16,884 
Net loss before tax recovery (expense)   (11,818)   (17,579)
Deferred income tax (expense) benefit   (83)   1,521 
Net loss   (11,901)   (16,058)
Cash payable on converted Series A Preferred Stock       (3,421)
Deemed dividends on Series A Preferred Stock   (8,392)    
Deemed dividend of on Series C Preferred Stock   (123)   (1,572)
Net loss attributable to common stockholders  $(20,416)  $(21,051)
           
Basic and diluted net loss per common stock  $(10.26)  $(3,093.42)
Weighted average number of common stock outstanding, basic and diluted   1,990,748    6,805 
Other comprehensive loss, net of tax:          
Net loss  $(11,901)  $(16,058)
Change in cumulative translation adjustment   310    (121)
Comprehensive loss attributable to common stockholders  $(11,591)  $(16,179)

 

All common share data has been retroactively adjusted to effect reverse stock splits in 2023.

 

 

Allarity Therapeutics, Inc. | 24 School Street, 2nd Floor | Boston, MA | U.S.A. | NASDAQ: ALLR  | www.allarity.com

 

Page 4 of 6

 

 

ALLARITY THERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEETS
As of December 31, 2023 and 2022
(U.S. dollars in thousands, except for share and per share data)

 

    December 31,     December 31,  
    2023     2022  
ASSETS            
Current assets:            
Cash   $ 166     $ 2,029  
Other current assets     209       1,559  
Prepaid expenses     781       591  
Tax credit receivable     815       789  
Total current assets     1,971       4,968  
Non-current assets:                
Property, plant and equipment, net     20       21  
Operating lease right of use assets           6  
Intangible assets     9,871       9,549  
Total assets   $ 11,862     $ 14,544  
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY                
Current liabilities:                
Accounts payable   $ 8,416     $ 6,251  
Accrued liabilities     1,309       1,904  
Warrant derivative liability     3,083       374  
Income taxes payable     59       41  
Convertible promissory note and accrued interest, net of debt discount     1,300        
Secured promissory notes           2,644  
Operating lease liabilities, current           8  
Total current liabilities     14,167       11,222  
Non-current liabilities:                
Convertible promissory note and accrued interest, net of debt discount           1,083  
Deferred tax     446       349  
Total liabilities     14,613       12,654  
Redeemable preferred stock (500,000 shares authorized)                
Series A Preferred Stock $0.0001 par value (20,000 shares designated) shares issued and outstanding at December 31, 2023 and 2022, were 1,417 and 13,586, respectively (liquidation preference of $17.54 at December 31, 2023)           2,001  
Series B Preferred Stock $0.0001 par value (200,000 shares designated); shares issued at December 31, 2023 and 2022, were 0 and 190,786, respectively (liquidation preference of $0 at December 31, 2023)           2  
Series C Convertible Preferred stock $0.0001 par value (50,000 and 0 shares designated at December 31, 2023 and 2022, respectively); shares issued and outstanding at December 31, 2023 were 0            
Total redeemable preferred stock           2,003  
Stockholders’ (deficit) equity                
Series A Preferred stock $0.0001 par value (20,000 shares designated) shares issued and outstanding at December 31, 2023 and 2022, were 1,417 and 13,586, respectively (liquidation preference of $17.54 at December 31, 2023)     1,742        
Common Stock, $0.0001 par value (750,000,000 and 30,000,000 shares authorized, at December 31, 2023 and 2022, respectively); shares issued and outstanding at December 31, 2023 and 2022, were 5,886,934 and 11,356, respectively            
Additional paid-in capital     90,369       83,158  
Accumulated other comprehensive loss     (411 )     (721 )
Accumulated deficit     (94,451 )     (82,550 )
Total stockholders’ deficit     (2,751 )     (113 )
Total liabilities, preferred stock and stockholders’ (deficit) equity   $ 11,862     $ 14,544  

 

All common share data has been retroactively adjusted to effect reverse stock splits in 2023.

 

###

 

 

Allarity Therapeutics, Inc. | 24 School Street, 2nd Floor | Boston, MA | U.S.A. | NASDAQ: ALLR  | www.allarity.com

 

Page 5 of 6

 

 

Company Contact:

 

investorrelations@allarity.com

 

Media Contact:

 

Thomas Pedersen

Carrotize PR & Communications

+45 6062 9390

tsp@carrotize.com

 

 

Allarity Therapeutics, Inc. | 24 School Street, 2nd Floor | Boston, MA | U.S.A. | NASDAQ: ALLR  | www.allarity.com

 

Page 6 of 6

 

GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end EX-101.SCH 4 allr-20240308.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 allr-20240308_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 allr-20240308_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Mar. 08, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 08, 2024
Entity File Number 001-41160
Entity Registrant Name ALLARITY THERAPEUTICS, INC.
Entity Central Index Key 0001860657
Entity Tax Identification Number 87-2147982
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 24 School Street
Entity Address, Address Line Two 2nd Floor
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02108
City Area Code 401
Local Phone Number 426-4664
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ALLR
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://allarity.com/role/Cover Cover Cover 1 false false All Reports Book All Reports allr-20240308.xsd allr-20240308_lab.xml allr-20240308_pre.xml ea0201409-8k_allarity.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0201409-8k_allarity.htm": { "nsprefix": "ALLR", "nsuri": "http://allarity.com/20240308", "dts": { "schema": { "local": [ "allr-20240308.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "allr-20240308_lab.xml" ] }, "presentationLink": { "local": [ "allr-20240308_pre.xml" ] }, "inline": { "local": [ "ea0201409-8k_allarity.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://allarity.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0201409-8k_allarity.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0201409-8k_allarity.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://allarity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001213900-24-020882-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-020882-xbrl.zip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b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end XML 17 ea0201409-8k_allarity_htm.xml IDEA: XBRL DOCUMENT 0001860657 2024-03-08 2024-03-08 iso4217:USD shares iso4217:USD shares false 0001860657 8-K 2024-03-08 ALLARITY THERAPEUTICS, INC. DE 001-41160 87-2147982 24 School Street 2nd Floor Boston MA 02108 401 426-4664 false false false false Common Stock, par value $0.0001 per share ALLR NASDAQ true false